Lineage Cell Therapeutics, Inc. is among the 15 Best Biotech Penny Stocks to Invest in Right Now, with a focus on developing cell therapies for neurological and ophthalmic disorders. Positive results from a Phase 1/2a trial for OpRegen show sustained vision improvements in patients with age-related macular degeneration. The company also treated its first chronic spinal cord injury patient and partnered with William Demant Invest A/S to develop a program targeting auditory nerve restoration. Financially, Lineage remains strong with $42.3 million in cash and doubled revenues in Q2 2025. CEO Brian M. Culley highlighted the company’s progress at investor conferences, emphasizing confidence in the pipeline and upcoming initiatives.

Read more at Yahoo Finance: Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial